
<http://bio2rdf.org/drugbank_resource:5eadc46c0e7bb9330e936402088accf3> a <http://schema.org/Organization> ;
	<http://schema.org/name> "Merck and co inc" .

<http://bio2rdf.org/drugbank:DB00303> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Ertapenem" ;
	<http://schema.org/description> "Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz&reg;. It is structurally very similar to meropenem in that it possess a 1-beta-methyl group. [Wikipedia]" ;
	<http://schema.org/drugClass> "Anti-Bacterial Agents" ;
	<http://schema.org/url> "https://schemaorg.metadatacenter.org/drugbank/DB00303.html" ;
	<http://schema.org/administrationRoute> "intramuscular; intravenous" , "intravenous" , "intramuscular" ;
	<http://schema.org/availableStrength> <http://bio2rdf.org/drugbank_resource:2135afba308acb820c6591b33bae1e2d> , <http://bio2rdf.org/drugbank_resource:3cbc5360b6546e605167c1ee465bd73a> , <http://bio2rdf.org/drugbank_resource:e3effadc235577edaa76dc369303eae0> ;
	<http://schema.org/clinicalPharmacology> "Ertapenem has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria." ;
	<http://schema.org/cost> <http://bio2rdf.org/drugbank_resource:128d9277bae4c57e0083d586f18d6af7> , <http://bio2rdf.org/drugbank_resource:c204d58f3946bf3ac8d7e81bf0fddf96> ;
	<http://schema.org/dosageForm> "Powder for solution" , "Injection, powder, lyophilized, for solution" ;
	<http://schema.org/interactingDrug> <http://bio2rdf.org/drugbank_resource:DB00303_DB01032> ;
	<http://schema.org/legalStatus> "Investigational" , "Approved" ;
	<http://schema.org/manufacturer> <http://bio2rdf.org/drugbank_resource:5eadc46c0e7bb9330e936402088accf3> ;
	<http://schema.org/mechanismOfAction> "The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In <i>Escherichia coli</i>, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Ertapenem is hydrolyzed by metallo-beta-lactamases." ;
	<http://schema.org/nonProprietaryName> "ERTAPENEM" , "(1R,5S,6S,8R,2'S,4's)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid" , "(4R,5S,6S)-3-((3S,5S)-5-((3-Carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid" ;
	<http://schema.org/identifier> "drugbank:DB00303" ;
	<http://schema.org/sameAs> <http://www.drugs.com/cdi/ertapenem.html> , <http://www.drugbank.ca/drugs/DB00303> , <http://www.rxlist.com/cgi/generic3/invanz.htm> .

<http://bio2rdf.org/drugbank_resource:128d9277bae4c57e0083d586f18d6af7> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "72.84999847412109375" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Invanz 1 gm add-vantage vial" .

<http://bio2rdf.org/drugbank_resource:2135afba308acb820c6591b33bae1e2d> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "1 g Injection, powder, lyophilized, for solution form with intravenous route" .

<http://bio2rdf.org/drugbank_resource:3cbc5360b6546e605167c1ee465bd73a> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "1 g Powder for solution form with intramuscular route" .

<http://bio2rdf.org/drugbank_resource:c204d58f3946bf3ac8d7e81bf0fddf96> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "69.40000152587890625" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Invanz 1 gm vial" .

<http://bio2rdf.org/drugbank_resource:e3effadc235577edaa76dc369303eae0> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "1 g Injection, powder, lyophilized, for solution form with intramuscular; intravenous route" .
